Aspen looks to expand output of vaccinations
Aspen Pharmacare is in discussions to expand its vaccine production capacity beyond Covid-19 to jabs
for other diseases, according to CEO Stephen Saad. Aspen has the capacity to produce up to 1.35-bn
vaccine doses at its sterile manufacturing facility in Gqeberha and is using less than a quarter of that capacity to help make Johnson & Johnson’s Covid-19 shot, reported Business Day (September 2021) The company aims to ramp up Covid-19 vaccine production from 300-m to 450-m doses a year by February, and to 700-m doses a year by January 2023, but would still have scope to make other kinds of shots.